AMX0035
Amylyx is currently exploring the potential of AMX0035 as a treatment option for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome.
Pipeline | Amylyx Skip to main content Pipeline We are tackling some of medicine’s toughest problems to serve communities with high unmet needs. To accomplish this, we are advancing a pipeline in which we’ve matched investigational therapies with diseases in which they can make the greatest impact, based on well-defined mechanistic rationale, clear clinical outcomes and biomarkers, and rigorous preclinical data. AVEXITIDE Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist designed to bind to the GLP-1 receptor on pancreatic islet beta cells and
Explore this link on the map →related reading
- ALS - Wikipediaen.wikipedia.org
- Research Areas - Svendsen Lab | Cedars-Sinaicedars-sinai.edu
- Gap Mapgap-map.org
- Amyloidosis - Symptoms, Causes, Treatment | NORDrarediseases.org
- ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? - PubMedpubmed.ncbi.nlm.nih.gov
- Blood biomarkers in ALS: challenges, applications and novel frontiers - PMCncbi.nlm.nih.gov
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- Sci-Hubsci-hub.box
- Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com
- Asimov — Intelligent Designasimov.com
- Asimov — Intelligent Designasimov.com
- Enteromeenterome.com